Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Jun;2(2):70-2.
doi: 10.1002/rcr2.52. Epub 2014 Feb 25.

Tacrolimus rescue therapy for severe respiratory failure in the anti-synthetase syndrome

Amy L Rigby  1 , Marshall Plit  1 , Allan R Glanville  1
Affiliations
Case Reports

Tacrolimus rescue therapy for severe respiratory failure in the anti-synthetase syndrome

Amy L Rigby et al. Respirol Case Rep. 2014 Jun.

Abstract

Interstitial lung disease (ILD) is the major determinant of morbidity and mortality in the anti-synthetase syndrome (ASS). The therapeutic efficacy of corticosteroids for the ILD component is limited; hence, additional immunosuppressive and immunomodulatory therapies have been tried with a modicum of success in recent years. Tacrolimus, a calcineurin inhibitor, is one potential therapy. We describe four consecutive patients with ASS whom we treated with tacrolimus at a quaternary referral hospital in 2009-2013. All four patients had significant ILD, three had severe and progressive ILD, and two had been referred for consideration of lung transplantation. Tacrolimus use was associated with improvement in ILD in all four patients with a mean follow-up of 3 years. Our case series adds further evidence to support the use of tacrolimus as salvage therapy for severe respiratory failure due to ILD in ASS, which may be associated with a dramatic and enduring response.

Keywords: Anti-synthetase syndrome; pulmonary fibrosis; tacrolimus.

PubMed Disclaimer

References

    1. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology. 2007;46:124–130. - PubMed
    1. Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome – a retrospective case series. Rheumatology. 2009;48:968–971. - PubMed
    1. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–2446. - PubMed
    1. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38:383–392. - PubMed
    1. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J. Rheumatol. 2000;27:2855–2859. - PubMed

Publication types

LinkOut - more resources